ASCO GU 2019 | oncinfo

Dr. Andrew J. Armstrong, Duke University, USA

Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.

Dr. Toni Choueiri, Dana-Farber Cancer Institute, USA

Highlights in RCC from ASCO GU 2019

Dr. Sumanta K. Pal, City of Hope, USA

Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC).

Dr. Brian Rini, Cleveland Clinic, USA

TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

Dr. Paulo Lajes, Dr. Fernando Maluf and Dr. Andrey Soares, Brazil

Take Home Messages from ASCO GU 2019 (Portuguese)

Dr. Manuel Maia, COP, Brazil

Updates in Prostate Cancer from ASCO GU2019

Dr. Steve Yip, BC Cancer Agency, Canada

Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

Dr. Arjun V Balar, NYU Langone's Pearlmutter Cancer Center, USA

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

Dr. Karine Trindade, Oncocentro, Brazil

Dr. Fernando Nunes, Clinica Clion, Brazil

Highlights in First Line RCC (Portuguese)

Dr. Orazio Caffo, Santa Chiara Hospital, Italy

A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.